Brief: United Therapeutics Announces FDA Clearance To Proceed With Summit Clinical Trial For Treprostinil Smi In Ph-Copd
19/10/2026 12:33
BRIEF-United Therapeutics Announces FDA Clearance To Proceed With Summit Clinical Trial For Treprostinil Smi In Ph-Copd Oct 19 (Reuters) - United Therapeutics Corporation UTHR.O:
UNITED THERAPEUTICS ANNOUNCES FDA CLEARANCE TO PROCEED WITH SUMMIT CLINICAL TRIAL FOR TREPROSTINIL SMI IN PH-COPD
UNITED THERAPEUTICS CORPORATION - ANTICIPATES PHASE 3 STUDY FOR TREPROSTINIL SMI IN PH-COPD IN 2028
Source text: ID:nBw2rbjKja
Further company coverage: UTHR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on United Therapeutics
See all newsBrief: United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization
Brief: United Therapeutics Announces FDA Clearance To Proceed With Summit Clinical Trial For Treprostinil Smi In Ph-Copd
Liquidia surges as United Therapeutics settlement removes key litigation risk (updated)
Brief: United Therapeutics Enters Settlement Agreement With Liquidia To Resolve Litigation - SEC Filing
Liquidia surges after $381 million settlement with United Therapeutics for lung disease drug